TY - JOUR T1 - Associations of habitual fish oil use with risk of SARS-CoV-2 infection and COVID-19-related outcomes in UK: national population based cohort study JF - medRxiv DO - 10.1101/2022.09.14.22279933 SP - 2022.09.14.22279933 AU - Yuying Ma AU - Lijun Zhang AU - Ruijie Zeng AU - Dongling Luo AU - Rui Jiang AU - Huihuan Wu AU - Zewei Zhuo AU - Qi Yang AU - Jingwei Li AU - Felix W Leung AU - Jinghua Wang AU - Weihong Sha AU - Hao Chen Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/09/17/2022.09.14.22279933.abstract N2 - Objectives To prospectively investigate the associations of habitual fish oil use with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospital admission, or mortality with Corona Virus Disease-19 (COVID-19) in a large-scale cohort.Design Prospective population-based cohort study.Setting UK Biobank.Participants A total of 110 440 participants aged 37 -73 years who completed a questionnaire on supplement use, which included fish oil at baseline were enrolled between 2006 and 2010 and followed up until 2022.Main exposure All participants filled out questionnaires about the habitual use of supplements, including fish oil.Main outcome measures SARS-CoV-2 infection, COVID-19 hospital admission and COVID-19 mortality.Results At baseline, 29 424 (26.6%) of the 110 440 participants reported habitual use of fish oil supplements. The multivariable adjusted hazard ratios for habitual users of fish oil versus non-users were 0.95 (0.93 to 0.98) for SARS-CoV-2 infection among participants with follow-up time less than 12.1 years but no significant associations were observed for participants with follow-up time more than 12.1 years. For COVID-19-related outcomes, the hazard ratios were 0.79 (95% confidence interval 0.71 to 0.88) for COVID-19 hospital admission and 0.72 (0.60 to 0.87) for COVID-19 mortality. For COVID-19-related outcomes, the association seemed to be stronger among those with longstanding illness. The Cox proportional hazard analysis after propensity-score matching yielded consistent results.Conclusions Habitual fish oil supplement is associated with a lower risk of hospital admission and mortality with COVID-19, but not associated with SARS-CoV-2 infection in the population with more than 12.1 years of follow-up.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Natural Science Foundation of China (82100238, 82171698, 82170561, 81300279, 81741067), the Program for High-level Foreign Expert Introduction of China (G2022030047L), the Natural Science Foundation for Distinguished Young Scholars of Guangdong Province (2021B1515020003), the Guangdong Basic and Applied Basic Research Foundation (2022A1515012081), the Climbing Program of Introduced Talents and High-level Hospital Construction Project of Guangdong Provincial People's Hospital (DFJH201803, KJ012019099, KJ012021143, KY012021183), the Science and Technology Program of Guangzhou (No. 202201011046), and in part by VA Clinical Merit and ASGE clinical research funds (FWL).xAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research ethics committee of the UK Biobank gave ethnical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript. ER -